Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2003 2
2004 2
2005 4
2006 1
2007 1
2008 1
2009 1
2011 5
2012 4
2013 6
2014 6
2015 7
2016 12
2017 8
2018 10
2019 10
2020 31
2021 26
2022 23
2023 29
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

168 results

Results by year

Filters applied: . Clear all
Page 1
Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study.
Straatmijer T, Biemans VBC, Visschedijk M, Hoentjen F, de Vries A, van Bodegraven AA, Bodelier A, de Boer NKH, Dijkstra G, Festen N, Horjus C, Jansen JM, Jharap B, Mares W, van Schaik FDM, Ponsioen C, Romkens T, Srivastava N, van der Voorn MMPJA, West R, van der Woude J, Wolvers MDJ, Pierik M, van der Meulen-de Jong AE, Duijvestein M; Initiative on Crohn and Colitis. Straatmijer T, et al. Among authors: hoentjen f. Clin Gastroenterol Hepatol. 2023 Jan;21(1):182-191.e2. doi: 10.1016/j.cgh.2022.04.038. Epub 2022 May 26. Clin Gastroenterol Hepatol. 2023. PMID: 35644343 Free article.
Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.
Yanai H, Kagramanova A, Knyazev O, Sabino J, Haenen S, Mantzaris GJ, Mountaki K, Armuzzi A, Pugliese D, Furfaro F, Fiorino G, Drobne D, Kurent T, Yassin S, Maharshak N, Castiglione F, de Sire R, Nardone OM, Farkas K, Molnar T, Krznaric Z, Brinar M, Chashkova E, Livne Margolin M, Kopylov U, Bezzio C, Bar-Gil Shitrit A, Lukas M, Chaparro M, Truyens M, Nancey S, Lobaton T, Gisbert JP, Saibeni S, Bacsúr P, Bossuyt P, Schulberg J, Hoentjen F, Viganò C, Palermo A, Torres J, Revés J, Karmiris K, Velegraki M, Savarino E, Markopoulos P, Tsironi E, Ellul P, Calviño Suárez C, Weisshof R, Ben-Hur D, Naftali T, Eriksson C, Koutroubakis IE, Foteinogiannopoulou K, Limdi JK, Liu E, Surís G, Calabrese E, Zorzi F, Filip R, Ribaldone DG, Snir Y, Goren I, Banai-Eran H, Broytman Y, Amir Barak H, Avni-Biron I, Ollech JE, Dotan I, Aharoni Golan M. Yanai H, et al. Among authors: hoentjen f. J Crohns Colitis. 2022 Dec 5;16(12):1882-1892. doi: 10.1093/ecco-jcc/jjac100. J Crohns Colitis. 2022. PMID: 35895074
Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis.
Westdorp H, Sweep MWD, Gorris MAJ, Hoentjen F, Boers-Sonderen MJ, van der Post RS, van den Heuvel MM, Piet B, Boleij A, Bloemendal HJ, de Vries IJM. Westdorp H, et al. Among authors: hoentjen f. Front Immunol. 2021 Oct 29;12:768957. doi: 10.3389/fimmu.2021.768957. eCollection 2021. Front Immunol. 2021. PMID: 34777387 Free PMC article. Review.
Endoscopic and surgical treatment outcomes of colitis-associated advanced colorectal neoplasia: a multicenter cohort study.
Derks ME, Te Groen M, Peters CP, Dijkstra G, de Vries AC, Romkens TE, Horjus CS, de Boer NK, Bemelman WA, Nagtegaal ID, Derikx LA, Hoentjen F; Dutch Initiative on Crohn and Colitis. Derks ME, et al. Among authors: hoentjen f. Int J Surg. 2023 Jul 1;109(7):1961-1969. doi: 10.1097/JS9.0000000000000335. Int J Surg. 2023. PMID: 37300890 Free PMC article.
Noninferiority or Nonsuperiority?
Groen MT, den Broeder N, Hoentjen F. Groen MT, et al. Among authors: hoentjen f. Gastroenterology. 2020 Dec;159(6):2248. doi: 10.1053/j.gastro.2020.02.070. Epub 2020 May 17. Gastroenterology. 2020. PMID: 32433982 No abstract available.
Probiotics and prebiotics in ulcerative colitis.
Derikx LA, Dieleman LA, Hoentjen F. Derikx LA, et al. Among authors: hoentjen f. Best Pract Res Clin Gastroenterol. 2016 Feb;30(1):55-71. doi: 10.1016/j.bpg.2016.02.005. Epub 2016 Feb 9. Best Pract Res Clin Gastroenterol. 2016. PMID: 27048897 Review.
Golimumab for the treatment of ulcerative colitis.
Löwenberg M, de Boer NKh, Hoentjen F. Löwenberg M, et al. Among authors: hoentjen f. Clin Exp Gastroenterol. 2014 Mar 12;7:53-9. doi: 10.2147/CEG.S48741. eCollection 2014. Clin Exp Gastroenterol. 2014. PMID: 24648749 Free PMC article. Review.
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, van der Woude CJ, Hoentjen F; LADI study group and the Dutch Initiative on Crohn and Colitis. van Linschoten RCA, et al. Among authors: hoentjen f. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):343-355. doi: 10.1016/S2468-1253(22)00434-4. Epub 2023 Jan 31. Lancet Gastroenterol Hepatol. 2023. PMID: 36736339 Clinical Trial.
168 results